Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of CPC-201 in Patients With Dementia of the Alzheimer's Type Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07

NCT02434666 is registered in ClinicalTrials.gov with Chase Pharmaceuticals Corporation, an affiliate of Allergan plc as lead sponsor.

NCT NCT02434666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02434666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of CPC-201 in Patients With Dementia of the Alzheimer's Type Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Phase
Phase 2
Overall status
Completed
Start date
January 8, 2015
Completion date
November 22, 2016
Enrollment
21 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

dementia of the alzheimer's type